Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), SURE-01 trial, radical cystectomy, neoadjuvant sacituzumab govitecan (SG), monotherapy, sacituzumab govitecan followed by radical ...

SNMMI 2025 positive predictive value of 18F-piflufolastat PET/CT, prostate/prostatic bed, patients with biochemical recurrence when stratified by PSA level at the time of imaging, CONDOR study.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein which functions as a zinc metalloenzyme and is found on prostatic epithelium. In normal prostate tissue, PSMA ...

WCET 2024 optimizing stone treatment, Michelle Jo Semins, laser modalities, world’s first ureteroscopy and laser lithotripsy, MOSES technology.

SNMMI 2025 clinical value of the PROSTest to detect biochemical recurrence in prostate cancer, PSMA-PET/CT, PSMA-PET/CT imaging, PROSTest, biochemical recurrence in prostate cancer.

AUA 2025 thermal safety of high-powered lasers during endoscopic stone surgery, renal calyceal, parenchymal temperatures, laser lithotripsy, 60W Super-Pulse Thulium Fiber Laser (TFL), 120W ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...